Payment overview · 2025
General Payments
$53.88
3 reported records · 3 companies
Healthcare provider profile · identity verified
Edward T Costello, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MALVERN, AR · NPI 1730104340
Verified facts
What the public records show
CMS Open Payments records show Edward T Costello, P.A. received $53.88 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.92 | 42.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.91 | 29.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.05 | 27.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.88 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Celecoxib | Celecoxib | 235 | 73 |
| Gabapentin | Gabapentin | 227 | 52 |
| Lisinopril | Lisinopril | 205 | 60 |
| Omeprazole | Omeprazole | 181 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 51 |
| Losartan Potassium | Losartan Potassium | 164 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 150 | 49 |
| Jardiance | Empagliflozin | 148 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 38 |
| Tramadol Hcl | Tramadol Hcl | 131 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 130 | 32 |
| Meloxicam | Meloxicam | 129 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 33 |
| Trazodone Hcl | Trazodone Hcl | 126 | 33 |
| Furosemide | Furosemide | 118 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 28 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 109 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 103 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 31 |
| Pregabalin | Pregabalin | 98 | 33 |
| Simvastatin | Simvastatin | 94 | 35 |
| Cephalexin | Cephalexin | 93 | 69 |
| Metformin Hcl Er | Metformin Hcl | 93 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 32 |
| Potassium Chloride | Potassium Chloride | 88 | 25 |
| Ozempic | Semaglutide | 87 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 20 |
| Eliquis | Apixaban | 75 | 20 |
| Glipizide | Glipizide | 75 | 21 |
| Famotidine | Famotidine | 72 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 18 |
| Clonazepam | Clonazepam | 67 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 18 |
| Metformin Hcl | Metformin Hcl | 65 | 17 |
| Carvedilol | Carvedilol | 63 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 18 |
| Sertraline Hcl | Sertraline Hcl | 59 | 20 |
| Buspirone Hcl | Buspirone Hcl | 58 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 24 |
| Prednisone | Prednisone | 52 | 20 |
| Allopurinol | Allopurinol | 51 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 12 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Alprazolam | Alprazolam | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 27 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.88 · 3 records | Abbott Laboratories | BREZTRI, CARDIOMEMS, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error